287 related articles for article (PubMed ID: 28655795)
1. First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP; Gluck L; Martin LP; Olszanski AJ; Tolcher AW; Ngarmchamnanrith G; Rasmussen E; Amore BM; Nagorsen D; Hill JS; Stephenson J
Clin Cancer Res; 2017 Oct; 23(19):5703-5710. PubMed ID: 28655795
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
Razak AR; Cleary JM; Moreno V; Boyer M; Calvo Aller E; Edenfield W; Tie J; Harvey RD; Rutten A; Shah MA; Olszanski AJ; Jäger D; Lakhani N; Ryan DP; Rasmussen E; Juan G; Wong H; Soman N; Smit MD; Nagorsen D; Papadopoulos KP
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046621
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
Herbst RS; Hong D; Chap L; Kurzrock R; Jackson E; Silverman JM; Rasmussen E; Sun YN; Zhong D; Hwang YC; Evelhoch JL; Oliner JD; Le N; Rosen LS
J Clin Oncol; 2009 Jul; 27(21):3557-65. PubMed ID: 19546406
[TBL] [Abstract][Full Text] [Related]
5. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
Rosen PJ; Sweeney CJ; Park DJ; Beaupre DM; Deng H; Leitch IM; Shubhakar P; Zhu M; Oliner KS; Anderson A; Yee LK
Clin Cancer Res; 2010 May; 16(9):2677-87. PubMed ID: 20406832
[TBL] [Abstract][Full Text] [Related]
6. A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.
Dowlati A; Vlahovic G; Natale RB; Rasmussen E; Singh I; Hwang YC; Rossi J; Bass MB; Friberg G; Pickett CA
Clin Cancer Res; 2016 Sep; 22(18):4574-84. PubMed ID: 27076631
[TBL] [Abstract][Full Text] [Related]
7. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.
Tran B; Carvajal RD; Marabelle A; Patel SP; LoRusso PM; Rasmussen E; Juan G; Upreti VV; Beers C; Ngarmchamnanrith G; Schöffski P
J Immunother Cancer; 2018 Sep; 6(1):93. PubMed ID: 30253804
[TBL] [Abstract][Full Text] [Related]
8. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma.
Massard C; Soria JC; Krauss J; Gordon M; Lockhart AC; Rasmussen E; Upreti VV; Patel S; Ngarmchamnanrith G; Henary H
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1057-1063. PubMed ID: 30915497
[TBL] [Abstract][Full Text] [Related]
9. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
Tolcher AW; Sarantopoulos J; Patnaik A; Papadopoulos K; Lin CC; Rodon J; Murphy B; Roth B; McCaffery I; Gorski KS; Kaiser B; Zhu M; Deng H; Friberg G; Puzanov I
J Clin Oncol; 2009 Dec; 27(34):5800-7. PubMed ID: 19786654
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.
LoRusso PM; Gounder M; Jalal SI; André V; Kambhampati SRP; Loizos N; Hall J; Holzer TR; Nasir A; Cosaert J; Kauh J; Chiorean EG
Invest New Drugs; 2017 Aug; 35(4):442-450. PubMed ID: 28161886
[TBL] [Abstract][Full Text] [Related]
11. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Cassier PA; Italiano A; Gomez-Roca CA; Le Tourneau C; Toulmonde M; Cannarile MA; Ries C; Brillouet A; Müller C; Jegg AM; Bröske AM; Dembowski M; Bray-French K; Freilinger C; Meneses-Lorente G; Baehner M; Harding R; Ratnayake J; Abiraj K; Gass N; Noh K; Christen RD; Ukarma L; Bompas E; Delord JP; Blay JY; Rüttinger D
Lancet Oncol; 2015 Aug; 16(8):949-56. PubMed ID: 26179200
[TBL] [Abstract][Full Text] [Related]
12. Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
Aftimos P; Rolfo C; Rottey S; Offner F; Bron D; Maerevoet M; Soria JC; Moshir M; Dreier T; Van Rompaey L; Michot JM; Silence K; Hultberg A; Gandini D; de Haard H; Ribrag V; Peeters M; Thibault A; Leupin N; Awada A
Clin Cancer Res; 2017 Nov; 23(21):6411-6420. PubMed ID: 28765328
[No Abstract] [Full Text] [Related]
13. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
Rosen LS; Kurzrock R; Mulay M; Van Vugt A; Purdom M; Ng C; Silverman J; Koutsoukos A; Sun YN; Bass MB; Xu RY; Polverino A; Wiezorek JS; Chang DD; Benjamin R; Herbst RS
J Clin Oncol; 2007 Jun; 25(17):2369-76. PubMed ID: 17557949
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
Gomez-Roca CA; Italiano A; Le Tourneau C; Cassier PA; Toulmonde M; D'Angelo SP; Campone M; Weber KL; Loirat D; Cannarile MA; Jegg AM; Ries C; Christen R; Meneses-Lorente G; Jacob W; Klaman I; Ooi CH; Watson C; Wonde K; Reis B; Michielin F; Rüttinger D; Delord JP; Blay JY
Ann Oncol; 2019 Aug; 30(8):1381-1392. PubMed ID: 31114846
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
Chiorean EG; Hurwitz HI; Cohen RB; Schwartz JD; Dalal RP; Fox FE; Gao L; Sweeney CJ
Ann Oncol; 2015 Jun; 26(6):1230-1237. PubMed ID: 25787923
[TBL] [Abstract][Full Text] [Related]
16. LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
Dowlati A; Harvey RD; Carvajal RD; Hamid O; Klempner SJ; Kauh JSW; Peterson DA; Yu D; Chapman SC; Szpurka AM; Carlsen M; Quinlan T; Wesolowski R
Invest New Drugs; 2021 Aug; 39(4):1057-1071. PubMed ID: 33624233
[TBL] [Abstract][Full Text] [Related]
17. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.
Carducci M; Shaheen M; Markman B; Hurvitz S; Mahadevan D; Kotasek D; Goodman OB; Rasmussen E; Chow V; Juan G; Friberg GR; Gamelin E; Vogl FD; Desai J
Invest New Drugs; 2018 Dec; 36(6):1060-1071. PubMed ID: 29980894
[TBL] [Abstract][Full Text] [Related]
18. Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.
Abramson VG; Supko JG; Ballinger T; Cleary JM; Hilton JF; Tolaney SM; Chau NG; Cho DC; Pearlberg J; Lager J; Shapiro GI; Arteaga CL
Clin Cancer Res; 2017 Jul; 23(14):3520-3528. PubMed ID: 28031425
[No Abstract] [Full Text] [Related]
19. Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII.
Rosenthal M; Curry R; Reardon DA; Rasmussen E; Upreti VV; Damore MA; Henary HA; Hill JS; Cloughesy T
Cancer Chemother Pharmacol; 2019 Aug; 84(2):327-336. PubMed ID: 31154523
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.
Chiorean EG; Sweeney C; Youssoufian H; Qin A; Dontabhaktuni A; Loizos N; Nippgen J; Amato R
Cancer Chemother Pharmacol; 2014 Mar; 73(3):595-604. PubMed ID: 24452395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
